Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC73019 Depatuxizumab mafodotin

    ABT-414

     Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin Chemical Structure
  3. GC19399 Derazantinib

    ARQ 087

     Derazantinib is a novel, ATP competitive, small molecule, multi-kinase inhibitor with IC50 of 1.8nM for FGFR2, and 4.5nM for FGFR1 and 3. Derazantinib Chemical Structure
  4. GC62107 DGY-06-116 DGY-06-116 is an irreversible covalent, selective Src inhibitor with an IC50 of 3nM. DGY-06-116 inhibits FGFR1 with an IC50 of 8340 nM. DGY-06-116 Chemical Structure
  5. GC73335 DHFR-IN-4 DHFR-IN-4 is a potent didrofolate reductase (DHFR) inhibitor with an IC50 value of 123 nM. DHFR-IN-4 Chemical Structure
  6. GC30768 Dihexa (PNB-0408) Dihexa (PNB-0408) (N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide) is an oral active, blood-brain barrier-permeable angiotensin IV analogue. Dihexa (PNB-0408) Chemical Structure
  7. GC68986 Disitamab

    RC48-0

    Disitamab (RC48-0) is a humanized monoclonal antibody that targets HER2. Disitamab can be used to synthesize antibody-drug conjugates (ADCs), such as Disitamab vedotin.

     Disitamab Chemical Structure
  8. GC64039 Disitamab vedotin

    Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.

     Disitamab vedotin Chemical Structure
  9. GC14298 DMH-1

    BMP Inhibitor II, DorsoMorphin Homolog 1, VU036482

     Selective BMP ALK2 receptor DMH-1 Chemical Structure
  10. GC17098 DMH4 VEGFR-2 inhibitor DMH4 Chemical Structure
  11. GC43503 DMHAPC-Chol

    Dimethyl Hydroxyethyl Aminopropane Carbamoyl Cholesterol Iodide

     DMHAPC-Chol is a cationic cholesterol. DMHAPC-Chol Chemical Structure
  12. GC17024 DMPQ dihydrochloride PDGFRβ inhibitor DMPQ dihydrochloride Chemical Structure
  13. GC69000 Dosimertinib-d5 mesylate

    Dosimertinib-d5 (mesylate) is an effective orally active EGFR inhibitor. It reduces the expression of p-EGFR and p-ERK proteins. Dosimertinib-d5 (mesylate) exhibits anti-proliferative and anti-tumor activity. Dosimertinib-d5 (mesylate) has potential for research in non-small cell lung cancer (NSCLC).

     Dosimertinib-d5 mesylate Chemical Structure
  14. GC13547 Dovitinib (TKI-258, CHIR-258)

    CHIR258, TKI-258

     Dovitinib (TKI-258, CHIR-258) (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib (TKI-258, CHIR-258) has potent antitumor activity. Dovitinib (TKI-258, CHIR-258) Chemical Structure
  15. GC10165 Dovitinib (TKI258) Lactate Dovitinib (TKI258) Lactate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. Dovitinib (TKI258) Lactate Chemical Structure
  16. GC11372 Dovitinib Dilactic acid FLT3 inhibitor Dovitinib Dilactic acid Chemical Structure
  17. GC32760 Dovitinib lactate (CHIR-258 lactate) Dovitinib lactate (CHIR-258 lactate) (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. Dovitinib lactate (CHIR-258 lactate) Chemical Structure
  18. GC45767 Dovitinib-d8 An internal standard for the quantification of dovitinib Dovitinib-d8 Chemical Structure
  19. GC35897 DPH A potent cell permeable c-Abl activator DPH Chemical Structure
  20. GC62597 DS-1205b free base DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo. DS-1205b free base Chemical Structure
  21. GC72453 Duligotuzumab Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody that specifically targets Her3 (ErbB3). Duligotuzumab Chemical Structure
  22. GC72454 Dusigitumab Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody that specifically targets IGF2 and IGF1. Dusigitumab Chemical Structure
  23. GC62946 DYRK1-IN-1 DYRK1-IN-1 is a highly selective and ligand-efficient DYRK1A inhibitor. DYRK1-IN-1 Chemical Structure
  24. GC70985 Dyrk1A-IN-3 Dyrk1A-IN-3 (Compound 8b), a highly selective dual-specificity tyrosine-regulated kinase 1A (DYRK1A)inhibitor, maintains high levels of DYRK1A binding affinity (IC50=76 nM). Dyrk1A-IN-3 Chemical Structure
  25. GC69031 Dyrk1A-IN-5

    Dyrk1A-IN-5 (compound 5j) is a potent and selective inhibitor of DYRK1A with an IC50 value of 6 nM. Dyrk1A-IN-5 dose-dependently reduces the phosphorylation of Thr434 in SF3B1, with an IC50 of 0.5 μM. Dyrk1A-IN-5 inhibits the phosphorylation of tau protein at Thr212, with an IC50 of 2.1 μM. Dyrk1A-IN-5 can be used for research on Down syndrome.

     Dyrk1A-IN-5 Chemical Structure
  26. GC62947 DYRKs-IN-1 hydrochloride DYRKs-IN-1 hydrochloride is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC50s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity. DYRKs-IN-1 hydrochloride Chemical Structure
  27. GC73544 DZD1516 DZD1516 is a potent and selective HER2 inhibitor (IC50=0.56 nM) with good blood-brain permeability. DZD1516 Chemical Structure
  28. GC12149 E-3810 E-3810 Chemical Structure
  29. GC69037 E7090

    E7090 is an effective selective FGFR inhibitor with oral activity, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM and 120 nM for FGFR1/FGFR2/FGFR3/FGFR4 respectively.

     E7090 Chemical Structure
  30. GC62696 E7090 succinate E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively. E7090 succinate Chemical Structure
  31. GC66432 EAI001 EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer. EAI001 Chemical Structure
  32. GC12281 EAI045 Inhibitor of L858R/T790M EGFR mutants EAI045 Chemical Structure
  33. GC91497 EB 47 (hydrochloride) EB 47 is an inhibitor of poly(ADP-ribose) polymerase 1 (PARP1; IC50 = 45 nM) and a dual site inhibitor of tankyrase 2 (TNKS2; IC50 = 45 nM). EB 47 (hydrochloride) Chemical Structure
  34. GC64730 EB-42486 EB-42486 is a novel, potent, and highly selective G2019S-LRRK2 inhibitor (IC50 < 0.2 nM). EB-42486 Chemical Structure
  35. GC32825 eCF506 An inhibitor of Src kinases eCF506 Chemical Structure
  36. GC67879 Edecesertib

    GS-5718

     Edecesertib Chemical Structure
  37. GC19418 Edicotinib

    JNJ-40346527; JNJ-527

     Edicotinib is a selective and orally available colony-stimulating factor-1 (CSF-1) receptor inhibitor, and has entered phase IIA clinical trial to study rheumatoid arthritis (RA) despite disease. Edicotinib Chemical Structure
  38. GC72468 Efruxifermin Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin Chemical Structure
  39. GC16183 EG00229

    Nrp1 inhibitor

     EG00229 Chemical Structure
  40. GC16321 EGF816 EGF816 (EGF816) is a covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min-1 on EGFR(L858R/790M) mutant, respectively. EGF816 Chemical Structure
  41. GC11312 EGFR Inhibitor

    Epidermal Growth Factor Receptor Inhibitor

     EGFR Inhibitor is a 4,6-disubstituted pyrimidine and is a potent, ATP-competitive, irreversible and highly selective EGFR inhibitor with an IC50of 21 nM. EGFR Inhibitor also inhibits mutant EGFRL858R and EGFRL861Q with IC50s of 63 nM and 4 nM, respectively. EGFR Inhibitor displays strong selectivity for EGFR over HER4 (IC50 = 7640 nM) and a panel of 55 other kinases. EGFR Inhibitor induces cells apoptosis and has antitumor activity. EGFR Inhibitor Chemical Structure
  42. GC35965 EGFR mutant-IN-1 EGFR mutant-IN-1, a 5-methylpyrimidopyridone derivative, is a potent and selective EGFRL858R/T790M/C797S mutant inhibitor with an IC50 of 27.5 nM, while being a significantly less potent for EGFRWT (IC50 >1.0 μM). EGFR mutant-IN-1 Chemical Structure
  43. GC65572 EGFR Protein Tyrosine Kinase Substrate EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate. EGFR Protein Tyrosine Kinase Substrate Chemical Structure
  44. GC73274 EGFR T790M/L858R-IN-2 EGFR T790M/L858R-IN-2 is a potent and selective EGFRT790M/L858R inhibitor with IC50 values of 3.5, 1290 nM for EGFRT790M/L858R, EGFR WT, respectively. EGFR T790M/L858R-IN-2 Chemical Structure
  45. GC62562 EGFR-IN-11 EGFR-IN-11 is a fourth-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) with an IC50 of 18 nM for triple mutant EGFRL858R/T790M/C797S. EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1. EGFR-IN-11 Chemical Structure
  46. GC64497 EGFR-IN-17 EGFR-IN-17 is a potent and selective inhibitor of the epidermal growth factor receptor ( IC50 0.0002 μM) to overcome C797S-mediated resistance. EGFR-IN-17 Chemical Structure
  47. GC33195 EGFR-IN-2 EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor. EGFR-IN-2 Chemical Structure
  48. GC19132 EGFR-IN-3 EGFR-IN-3 is a third-generation EGFR TKI, with GI50 values of 5 nM (EGFR L858R/T790M), 10 nM (EGFR del19) and 689 nM (EGFR WT), respectively. EGFR-IN-3 has the potential for NSCLC research. EGFR-IN-3 Chemical Structure
  49. GC66428 EGFR-IN-5 EGFR-IN-5 is a EGFR inhibitor with IC50s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFRL858R, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively. EGFR-IN-5 Chemical Structure
  50. GC68440 EGFR-IN-69 EGFR-IN-69 Chemical Structure
  51. GC35966 EGFR-IN-7 EGFR-IN-7 is a potent, selective and orally active EGFR kinase inhibitor. EGFR-IN-7 has inhibitory effect for for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) with IC50 values of 7.92 nM and 0.218 nM, respectively. EGFR-IN-7 shows anti-tumor activity. EGFR-IN-7 can be used for the research of various cancers. EGFR-IN-7 Chemical Structure
  52. GC69043 EGFR-IN-70

    EGFR-IN-70 (compound 18j) is an effective EGFR inhibitor with IC50 values of 23.6 and 307.5 nM for EGFRLR/TM/CS and EGFRWT, respectively. It has anti-proliferative activity and inhibits the phosphorylation of EGFR. EGFR-IN-70 can be used in cancer research.

     EGFR-IN-70 Chemical Structure
  53. GC65974 EGFR-IN-9 EGFR-IN-9 (Compound 8) is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity. EGFR-IN-9 Chemical Structure
  54. GC73753 EGFR/AURKB-IN-1 EGFR/AURKB-IN-1 (compound 7) is a dual-targeted EGFR/AURKB inhibitor, and inhibits the phpsphorylations of L858R EGFR and AURKB with IC50s of 0.07 and 1.1, respectively. EGFR/AURKB-IN-1 Chemical Structure
  55. GC14856 EGFR/ErbB2 Inhibitor EGFR/ErbB2 Inhibitor (Compound 5) is a EGFR and ErbB inhibitor with IC50s of 0.017 μM, 0.08 μM, 1.91 μM. EGFR/ErbB2 Inhibitor Chemical Structure
  56. GC73415 EGFR/HER2-IN-9 EGFR/HER2-IN-9 (Compound 1) is an EGFR and HER2 inhibitor with IC50s of 3.2, 8.3 and 14 nM against EGFR, EGFR T790M and HER2, respectively. EGFR/HER2-IN-9 Chemical Structure
  57. GC25367 Ehp-inhibitor-1

    Ehp inhibitor 2

     Ehp-inhibitor-1 (Ehp inhibitor 2) is an Eph family tyrosine kinase inhibitor that targets Eph receptors. Ehp-inhibitor-1 Chemical Structure
  58. GC38330 EHT 5372 EHT 5372 Chemical Structure
  59. GC69050 Elenestinib

    BLU-263

    Elenestinib (BLU-263) is an effective orally active inhibitor of tyrosine kinase. Elenestinib has the potential to study systemic mastocytosis (SM).

     Elenestinib Chemical Structure
  60. GC74615 Elgemtumab

    LJM716

     Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab Chemical Structure
  61. GC10466 EMD-1214063 EMD-1214063 (Tepotinib, MSC2156119J) is a novel potent and highly selective reversible, ATP-competitive small molecule c-Met inhibitor . EMD-1214063 Chemical Structure
  62. GC60805 EMI48 EMI48, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI48 inhibits EGFR triple mutants. EMI48 Chemical Structure
  63. GC62420 EMI56 EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants. EMI56 Chemical Structure
  64. GC69058 Emibetuzumab

    LY2875358

    Emibetuzumab (LY2875358) is a humanized bivalent MET antibody of the IgG4 type. Emibetuzumab has high neutralizing and internalizing activity, effectively inhibiting the activation and tumor growth of both HGF-dependent and independent MET pathways. Emibetuzumab can be used for cancer research.

     Emibetuzumab Chemical Structure
  65. GC73405 Emzeltrectinib Emzeltrectinib is a potent tyrosine kinase inhibitor with antineoplastic activity. Emzeltrectinib Chemical Structure
  66. GC69061 Enapotamab

    Anti-AXL/UFO Reference Antibody (enapotamab)

    Enapotamab is an AXL/UFO-related antibody that can be used to synthesize Bcl-xl inhibitor antibody activity molecule conjugates.

     Enapotamab Chemical Structure
  67. GC65354 Enbezotinib Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer. Enbezotinib Chemical Structure
  68. GC16519 ENMD-2076 A multi-kinase inhibitor ENMD-2076 Chemical Structure
  69. GC12145 ENMD-2076 L-(+)-Tartaric acid ENMD-2076 L-(+)-Tartaric acid Chemical Structure
  70. GC33190 Ensartinib (X-396)

    X-396

     Ensartinib (X-396) (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. Ensartinib (X-396) Chemical Structure
  71. GC32864 Ensartinib hydrochloride (X-396 hydrochloride)

    X-396 dihydrochloride

     Ensartinib hydrochloride (X-396 hydrochloride) (X-396 dihydrochloride) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. Ensartinib hydrochloride (X-396 hydrochloride) Chemical Structure
  72. GC38776 Ensulizole Ensulizole is a sulfonated UV absorber and can intense UVB and partial UVA absorption. Ensulizole Chemical Structure
  73. GC73398 ENT-C225 ENT-C225 is an effective activator of TrkB neurotrophin receptor. ENT-C225 Chemical Structure
  74. GC70577 Entacapone acid Entacapone acid (Tyrphostin AG1290) is a tyrosine kinase inhibitor. Entacapone acid Chemical Structure
  75. GC14476 Entrectinib

    NMS-E628, RXDX-101

     Orally active inhibitor of ALK kinase Entrectinib Chemical Structure
  76. GC72974 Entrectinib-d8

    NMS-E628-d8; RXDX-101-d8

     Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib. Entrectinib-d8 Chemical Structure
  77. GC65380 Envonalkib Envonalkib is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib can be used for the research of non-small cell lung cancer. Envonalkib Chemical Structure
  78. GC33048 Epertinib (S-22611) Epertinib (S-22611) (S-22611) is a potent, oral, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib (S-22611) shows potent antitumor activity. Epertinib (S-22611) Chemical Structure
  79. GC38350 Epertinib hydrochloride

    S-22611 hydrochloride

     Epertinib hydrochloride (S-22611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride shows potent antitumor activity. Epertinib hydrochloride Chemical Structure
  80. GC69075 Epidermal growth factor (EGF) (phosphate)

    Epidermal growth factor (EGF) is an effective epidermal growth factor that stimulates the proliferation of skin cells and is used for wound healing applications.

     Epidermal growth factor (EGF) (phosphate) Chemical Structure
  81. GC62384 Epitinib succinate

    HMPL-813 succinate

     Epitinib succinate is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib succinate can be used for the research of cancer. Epitinib succinate Chemical Structure
  82. GC63390 EPQpYEEIPIYL EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains. EPQpYEEIPIYL Chemical Structure
  83. GC12958 ER 27319 maleate Selective inhibitor of Syk kinase ER 27319 maleate Chemical Structure
  84. GC70810 ER-27319 ER-27319, an acridone derivative, is a potent and selective SYK inhibitor, and inhibits the tyrosine phosphorylation of SYK and its activity. ER-27319 Chemical Structure
  85. GC74374 ErbB-2-binding peptide

    HER2-binding peptide

     ErbB-2-binding peptide (HER2-binding peptide) is a tumor-binding peptide. ErbB-2-binding peptide Chemical Structure
  86. GC52516 Erbstatin

    Antibiotic MH 435A

     A tyrosine kinase inhibitor Erbstatin Chemical Structure
  87. GC19142 Erdafitinib

    Erdafitinib

     A pan-FGFR tyrosine kinase inhibitor Erdafitinib Chemical Structure
  88. GC10627 Erlotinib

    NSC 718781

     Erlotinib is a potent and orally bioavailable epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with an IC50 value of 2 nM. Erlotinib Chemical Structure
  89. GC60154 Erlotinib D6

    CP-358774-d6; NSC 718781-d6; OSI-774-d6

     Erlotinib D6 (CP-358774 D6) is a deuterium labeled Erlotinib (CP-358774). Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR. Erlotinib D6 Chemical Structure
  90. GC15600 Erlotinib Hydrochloride

    CP-358774 hydrochloride; NSC 718781 hydrochloride; OSI-774 hydrochloride

     An EGFR tyrosine kinase inhibitor Erlotinib Hydrochloride Chemical Structure
  91. GC36003 Erlotinib mesylate EGFR inhibitor Erlotinib mesylate Chemical Structure
  92. GC62958 Erlotinib-13C6

    CP-358774-13C6; NSC 718781-13C6; OSI-774-13C6

     Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib-13C6 Chemical Structure
  93. GC47303 Erlotinib-d6 (hydrochloride) An internal standard for the quantification of erlotinib Erlotinib-d6 (hydrochloride) Chemical Structure
  94. GC47321 Etifoxine-13C-d3 A neuropeptide with diverse biological activities Etifoxine-13C-d3 Chemical Structure
  95. GC36021 F-1 F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively. F-1 Chemical Structure
  96. GC12174 FAK Inhibitor 14

    Focal Adhesion Kinase Inhibitor 14, NSC 667249, NSC 677249, Y15

     FAK Inhibitor 14 is a potent and specific inhibitor of focal adhesion kinase (FAK) that inhibits its autophosphorylation activity, decreases the viability of cancer cells, and blocks tumor growth. FAK Inhibitor 14 Chemical Structure
  97. GC36025 FAK inhibitor 2 FAK inhibitor 2 is a potent focal adhesion kinase (FAK) inhibitor with an IC50 ?of 0.07?nM, with antitumor and anti-angiogenesis activities. FAK inhibitor 2 Chemical Structure
  98. GC73575 FAK-IN-14 FAK-IN-14 (compound 8d) is a focal adhesion kinase(FAK) inhibitor with an IC50 value of 0.2438 nM. FAK-IN-14 Chemical Structure
  99. GC68030 FAK-IN-7 FAK-IN-7 Chemical Structure
  100. GC64836 Famitinib Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis. Famitinib Chemical Structure
  101. GC38437 Fangchinoline

    7-O-Demethyltetrandrine, Hanfangchin B, NSC 77036

     An alkaloid with diverse biological activities Fangchinoline Chemical Structure

Items 401 to 500 of 1359 total

per page
  2. 3
  3. 4
  4. 5
  5. 6
  6. 7

Set Descending Direction